According to Future Market Insights, progressive pulmonary fibrosis (PPF) treatment is expected to grow at a CAGR of 7.5% between 2023 and 2033, reaching US$ 7.7 Million in 2033. Sales grew at a CAGR of 6.3% from 2018 to 2023. As a result of the proliferation of ideal drugs to treat progressive pulmonary fibrosis and favorable reimbursement policies offered by manufacturers and insurance companies. Progressive pulmonary fibrosis market growth is driven by several key factors, like an increase in geriatric population, fibrotic disease prevalence, as well as technological advancements in cancer screening and diagnosis.
Moreover, new treatment options and cost-effective drugs are driving the market’s growth. The diagnosis of interstitial lung disease is usually made using imaging tests, such as X-rays and computed tomography (CT scans). PPF severity level is calculated based on the FVC score calculated as a measure of the severity level of Progressive pulmonary fibrosis (PPF). PPF treatment has witnessed a rapid growth in demand due to technological advancements and growing demand for minimally invasive surgeries.
๐ฎ๐๐ ๐ณ๐๐๐๐๐ ๐บ๐๐๐๐๐ ๐ช๐๐๐@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16356
Pulmonologists, radiologists, and pathologists are usually involved in the differential diagnosis of Interstitial lung diseases. As part of the evaluation, patients are observed clinically, given specific medical histories, assessed for smoking, examined for lung function, and have their serological test results analyzed, images are taken, and if necessary, a lung biopsy is performed. As GenZ smoking populations continue to increase and hereditary lung disease conditions become more prevalent, treatment diagnosis and drug development will be expected to expand as well. A rise in pollution across a variety of countries has also contributed to the growth of the market. PPF treatments have seen increased market growth due to increased consumer awareness about lung diseases and COVID-19.
Key Takeaways from the Market Studyโฏ
- The global market size for progressive pulmonary fibrosis (PPF) treatment is estimated to reach US$ 3.72 Million by 2023.
- According to the forecast, the market is expected to grow by 7.5% between 2023 and 2033, reaching a total of US$ 7.7 Million by 2033.
- The MAPK inhibitors pulmonary fibrosis (PPF) treatment market accounted for 11% of the total market value in 2023.
- Progressive pulmonary fibrosis (PPF) treatment in North America expanded with a market share of 51% in 2022.
- The retail pharmacies market is expected to account for 52.6% of the total market value by 2023.
โTissue transplants, new gene therapies, the development of new drugs for pulmonary fibrosis, artificial intelligence and technology all will contribute to the growth of progressive pulmonary fibrosis treatments.โ comments a Future Market Insights analyst.
๐จ๐๐ ๐จ๐ ๐จ๐๐๐๐๐๐@ https://www.futuremarketinsights.com/ask-question/rep-gb-16356
Competitive Landscapeโฏ
Several companies are expected to expand their product lines, acquire other companies, and merge in the coming years in response to the need for innovative diagnostic techniques.
- Boehringer Ingelheim (Canada) Ltd. is announced that OFEVยฎ (nintedanib), is approved for public reimbursement in Quebec, Ontario, Alberta, New Brunswick, Newfoundland and Labrador, Northwest Territories, and through the Non-Insured Health Benefits (NIHB) program for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD). ILD patients who rely on public reimbursement for their medications and who live with chronic fibrosing ILDs will be happy to hear this news. To ensure all pulmonary fibrosis patients receive treatment for managing their chronic disease, the firm encourages other provinces and territories to follow suit.
- In December 2022, PureTech Health plc reported on its Wholly Owned Programs1 and Founded Entities2 in 2022, which focused on changing the treatment paradigm for devastating diseases. Purtech’s Wholly Owned Programs aim to develop breakthrough drugs for patients with severe diseases that are underserved. There are several devastating conditions that the Company’s therapeutic candidates are targeting, including idiopathic pulmonary fibrosis (IPF), metastatic solid tumors, leukemia, and certain neurological conditions.
More Valuable Insightsโฏ
Future Market Insights, in its new offering, presents an unbiased analysis of the global progressive pulmonary fibrosis (PPF) treatment market, presenting a historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.
The study reveals essential insights on the basis of by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), by Treatment (Self Care, Medicines, (Pirfenidane, Nintedanib, Others) Lung Transplant, Palliative Care) and regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
๐ฉ๐๐ ๐ต๐๐/๐ท๐๐๐๐๐๐๐@ https://www.futuremarketinsights.com/checkout/16356
About the Healthcare Division at Future Market Insightsโฏ
The healthcare domain at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with the objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
Key Segments Profiled in the Progressive Pulmonary Fibrosis (PPF) Treatment Market Industry Survey?
By Treatment Type:
- MAPK Inhibitor
- Tyrosine Inhibitor
- Autotaxin Inhibitors
By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Treatment:
- Self-Care
- Medicines
- Pirfenidone
- Nintedanib
- Others
- Lung Transplant
- Palliative Care
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries:ย sales@futuremarketinsights.com
Browse All Reports :ย https://www.futuremarketinsights.com/reports
LinkedIn|ย Twitter|ย Blogs